MORAb-066 - Pancreatic Cancer Treatment


MORAb-066 is an investigational, humanized, IgG monoclonal antibody that targets Tissue Factor (TF), a membrane-bound antigen overexpressed in tumor cells and tumor endothelial cells. TF promotes tumor angiogenesis and cancer cell proliferation, and it inhibits apoptosis by indirectly activating Protease Activated Receptors (PARs). MORAb-066 has been investigated in a Phase 1 study in patients with advanced cancer. MORAb-066 has U.S. FDA orphan drug designation for pancreatic cancer.

Current Studies

MORAb-066 Phase 1 Study (Completed)

This study was a Phase 1, first-in-human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets tissue factor (TF) expressing malignancies, such as breast, pancreatic, colorectal, and non-small-cell lung cancer (NSCLC) (adenocarcinoma). This open-label study assessed the safety, tolerability, and pharmacokinetics of MORAb-066 administered weekly.

For more information, visit (Identifier: NCT01761240)

The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.